NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Synergy Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGYP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGYP

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Synergy Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for SGYP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Synergy Pharmaceuticals. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/26/2018Canaccord GenuityDowngradeBuy ➝ HoldN/A
10/26/2018BTIG ResearchDowngradeBuy ➝ NeutralN/A
8/7/2018HC WainwrightReiterated RatingBuy$7.00High
6/24/2018Cantor FitzgeraldReiterated RatingHoldHigh
6/6/2018HC WainwrightSet Price TargetBuy$7.00High
5/14/2018BTIG ResearchSet Price TargetBuy$7.00Low
5/13/2018HC WainwrightSet Price TargetBuy$7.00Low
5/13/2018OppenheimerReiterated RatingHoldLow
5/7/2018HC WainwrightSet Price TargetBuy$7.00High
3/22/2018OppenheimerReiterated RatingHoldLow
3/5/2018HC WainwrightSet Price TargetBuy$7.00Medium
3/1/2018OppenheimerReiterated RatingHoldHigh
2/1/2018HC WainwrightReiterated RatingBuy$7.00High
2/1/2018Cantor FitzgeraldReiterated RatingBuyHigh
1/25/2018Cantor FitzgeraldReiterated RatingBuy$10.00High
1/22/2018OppenheimerReiterated RatingHoldHigh
1/8/2018HC WainwrightSet Price TargetBuy$7.00Medium
1/5/2018OppenheimerReiterated RatingOutperform ➝ Market Perform$10.00High
1/5/2018CIBCReiterated RatingOutperform ➝ Market PerformHigh
1/5/2018CitigroupDowngradeMarket PerformHigh
1/4/2018OppenheimerDowngradeOutperform ➝ Market PerformHigh
12/4/2017HC WainwrightSet Price TargetBuy$7.00High
11/21/2017Cantor FitzgeraldReiterated RatingBuy$10.00N/A
11/14/2017BTIG ResearchReiterated RatingBuy$7.00N/A
11/12/2017Canaccord GenuitySet Price TargetBuy$13.00N/A
10/18/2017HC WainwrightSet Price TargetBuy$8.00N/A
10/11/2017HC WainwrightSet Price TargetBuy$8.00N/A
10/10/2017OppenheimerSet Price TargetBuy$6.00N/A
9/25/2017HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $8.00Low
9/13/2017CitigroupReiterated RatingSell ➝ Sell$3.20 ➝ $2.50Medium
9/8/2017BTIG ResearchReiterated RatingBuy$11.00Medium
9/8/2017CIBCLower Price TargetOutperform ➝ Outperform$9.00 ➝ $6.00Low
9/8/2017Cantor FitzgeraldReiterated RatingOverweight$11.00Medium
9/8/2017OppenheimerLower Price TargetOutperform$9.00 ➝ $6.00Medium
8/10/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$18.00 ➝ $15.00High
8/10/2017HC WainwrightSet Price TargetBuy$15.00High
8/10/2017OppenheimerSet Price TargetBuy$9.00High
8/10/2017Cantor FitzgeraldReiterated RatingBuy$11.00High
7/31/2017Canaccord GenuitySet Price TargetBuy$13.00Low
7/18/2017OppenheimerReiterated RatingOutperform$9.00Low
7/10/2017Canaccord GenuityReiterated RatingBuy$13.00Low
6/28/2017CitigroupReiterated RatingSell$3.70Low
6/27/2017BTIG ResearchReiterated RatingBuy$11.00High
6/14/2017Rodman & RenshawReiterated RatingBuy$18.00Medium
6/12/2017HC WainwrightReiterated RatingBuy$18.00Low
6/9/2017Cantor FitzgeraldReiterated RatingOverweight$11.00Low
6/1/2017Cantor FitzgeraldInitiated CoverageOverweight$11.00High
5/31/2017BTIG ResearchReiterated RatingBuy$11.00Low
5/23/2017Rodman & RenshawReiterated RatingBuy$18.00High
5/19/2017HC WainwrightReiterated RatingBuy$18.00Low
5/19/2017Canaccord GenuityReiterated RatingBuy$13.00Low
5/10/2017OppenheimerSet Price TargetBuy$10.00 ➝ $9.00Medium
4/22/2017BTIG ResearchReiterated RatingBuy$11.00Low
4/11/2017BTIG ResearchReiterated RatingBuy$11.00Low
4/6/2017CitigroupDowngradeNeutral ➝ SellHigh
3/29/2017Rodman & RenshawReiterated RatingBuy$18.00Low
3/28/2017HC WainwrightReiterated RatingBuy$18.00Medium
3/21/2017BTIG ResearchReiterated RatingBuy$11.00Low
3/16/2017HC WainwrightSet Price TargetBuy$18.00High
3/3/2017Rodman & RenshawReiterated RatingBuy$18.00N/A
3/2/2017OppenheimerSet Price TargetBuy$10.00N/A
3/2/2017Canaccord GenuitySet Price TargetBuy$13.00N/A
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/A
1/31/2017OppenheimerReiterated RatingOutperform$10.00N/A
1/28/2017Canaccord GenuityReiterated RatingBuy$13.00N/A
1/27/2017HC WainwrightSet Price TargetBuy$18.00N/A
1/26/2017BTIG ResearchReiterated RatingPositive$11.00N/A
1/21/2017Canaccord GenuitySet Price TargetBuy$13.00N/A
1/21/2017OppenheimerSet Price TargetBuy$10.00N/A
1/20/2017BTIG ResearchReiterated RatingBuy$11.00N/A
1/20/2017Rodman & RenshawBoost Price TargetBuy$17.00 ➝ $18.00N/A
1/4/2017OppenheimerInitiated CoverageOutperform$10.00N/A
12/31/2016Rodman & RenshawBoost Price TargetBuy$16.00 ➝ $17.00N/A
12/23/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
12/23/2016Rodman & RenshawBoost Price TargetBuy$16.00 ➝ $17.00N/A
12/23/2016BTIG ResearchReiterated RatingBuy$11.00N/A
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/A
12/13/2016Rodman & RenshawReiterated RatingBuy$15.00 ➝ $16.00N/A
12/12/2016HC WainwrightSet Price TargetBuy$16.00N/A
12/9/2016Canaccord GenuitySet Price TargetBuy$13.00N/A
12/6/2016BTIG ResearchReiterated RatingBuy$11.00N/A
11/30/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
11/14/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
11/11/2016Rodman & RenshawReiterated RatingBuy$15.00N/A
10/24/2016HC WainwrightSet Price TargetBuy$15.00N/A
10/21/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
10/17/2016BTIG ResearchReiterated RatingPositive$11.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Synergy Pharmaceuticals logo
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.02
Low: $0.01
High: $0.03

52 Week Range

Now: N/A

Volume

N/A

Average Volume

6,081,307 shs

Market Capitalization

$7.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Synergy Pharmaceuticals?

The following equities research analysts have issued research reports on Synergy Pharmaceuticals in the last twelve months:
View the latest analyst ratings for SGYP.

What is the current price target for Synergy Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Synergy Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Synergy Pharmaceuticals in the next year.
View the latest price targets for SGYP.

What is the current consensus analyst rating for Synergy Pharmaceuticals?

Synergy Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SGYP.

What other companies compete with Synergy Pharmaceuticals?

How do I contact Synergy Pharmaceuticals' investor relations team?

Synergy Pharmaceuticals' physical mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company's listed phone number is 212-297-0020 and its investor relations email address is [email protected] The official website for Synergy Pharmaceuticals is www.synergypharma.com.